EGFR exon 20 mutation	Solid Tumor	EGFR exon 20 mutation	Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	firmonertinib Sensitive: C2 – Inclusion Criteria firmonertinib Sensitive : C2	firmonertinib Sensitive: C2 – Inclusion Criteria firmonertinib Sensitive : C2
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3

EGFR exon 20 mutation

Associations